Keywords: pfizer, 3rd-qtr, profit, triples, due, exubera, write-off
Pfizer's 3rd-qtr 2008 profit triples due to Exubera write-off; revenues flat at $12B
Article | 27 October 2008
Pfizer's third-quarter 2008 profit tripled year-on-year as the comparative period was impacted by costs related to the firm's decision to stop ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
